GO
Loading...

Bone disease breakthrough

Thursday, 26 Jun 2014 | 5:45 PM ET

Emil Kakkis, Ultragenyx founder & CEO, discusses the beginning of its drug KRN23's phase 2 pediatric study to treat 30 kids with bone disorder X-linked hypophosphatemia (XLH).